{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-012608","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.510184+00:00","generated_at":"2026-06-06T04:23:45.756885+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Onconetix appoints Thomas Meier to board per Series B preferred holders' right","bullets":["Thomas Meier, PhD appointed as Class I director, term through 2025 annual meeting.","Meier has 25+ years biotech experience; chairs Santhera Pharmaceuticals (SIX:SANN).","Consulting agreement: CHF 400/hr as sellers' rep (Proteomedix deal) and CHF 350/hr as advisor.","Appointment effective Feb 6, 2024; ratified by Audit Committee Feb 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-012608","json":"https://secwatch.observer/filing/0001213900-24-012608.json","markdown":"https://secwatch.observer/filing/0001213900-24-012608.md","text":"https://secwatch.observer/filing/0001213900-24-012608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024012608/0001213900-24-012608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024012608/ea193470-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:23:45.756885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba5798cc0c","claim":"Thomas Meier was appointed as Director at Onconetix, Inc..","evidence_excerpt":"On February 6, 2024, pursuant to the Certificate of Designation of Series B Convertible Preferred Stock, the holders of Series B Convertible Preferred Stock appointed Thomas Meier, PhD, to the board of directors of Onconetix, Inc. (the “ Company ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024012608/0001213900-24-012608-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}